⌕
Xeris Biopharma Holdings · XERS · Nasdaq
Tenet 48 · Mixed
Compare
$16.70+0.24%At closeTenet 48 · Mixed
$16.70+0.04 (+0.24%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Xeris Biopharma Holdings (XERS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is XERS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 12, 2026 · 11:11 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma: Time For A Pause

Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth …

XERS +0.2% todayRead at source ↗
● MarketBeatNov 6, 2026 · 18:17 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma Q3 Earnings Call Highlights

Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.…

XERS +0.2% todayRead at source ↗
● Defense WorldNov 6, 2026 · 02:41 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma (NASDAQ:XERS) Reaches New 12-Month High on Better-Than-Expected Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) shares hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $1…

XERS +0.2% todayRead at source ↗
● Seeking AlphaNov 5, 2026 · 19:44 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Fi…

XERS +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:36 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates

Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.…

XERS +0.2% todayRead at source ↗
● Zacks Investment ResearchNov 5, 2026 · 10:31 ETEARNINGS EXPECTED BY JAN 25
Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimate…

XERS +0.2% todayRead at source ↗
● Business WireNov 5, 2026 · 07:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commerc…

XERS +0.2% todayRead at source ↗
● Defense WorldNov 3, 2026 · 03:45 ET
Xeris Biopharma (NASDAQ:XERS) vs. Cocrystal Pharma (NASDAQ:COCP) Head-To-Head Contrast

Cocrystal Pharma (NASDAQ: COCP - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses bas…

XERS +0.2% todayRead at source ↗
● Business WireNov 2, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commerc…

XERS +0.2% todayRead at source ↗
● GuruFocusOct 23, 2026 · 20:13 ET
Xeris Biopharma Holdings Inc (XERS) Stock Down 6.1% but Still Overvalued -- GF Score: 66/100

On October 23, 2026, Xeris Biopharma Holdings Inc (XERS) shares fell 6.1% to a current price of $10.20, within a 52-week range of $5.25 to $11.42. This price mo…

XERS +0.2% todayRead at source ↗
● Business WireOct 22, 2026 · 08:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commer…

XERS +0.2% todayRead at source ↗
● Defense WorldOct 17, 2026 · 03:29 ETEARNINGS EXPECTED BY JAN 25
Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS) Critical Comparison

Organon and Co. (NYSE: OGN - Get Free Report) and Xeris Biopharma (NASDAQ: XERS - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength…

XERS +0.2% todayRead at source ↗
● Business WireOct 15, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.…

XERS +0.2% todayRead at source ↗
● Defense WorldOct 4, 2026 · 14:14 ETEARNINGS EXPECTED BY JAN 25
Analyzing Xeris Biopharma (NASDAQ:XERS) and Corcept Therapeutics (NASDAQ:CORT)

Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on th…

XERS +0.2% todayRead at source ↗
● Business WireOct 2, 2026 · 17:00 ETCOMPANY'S OWN WORDS
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …

XERS +0.2% todayRead at source ↗
● Defense WorldSep 30, 2026 · 06:21 ET
Xeris Biopharma (NASDAQ:XERS) Shares Climb 5.2% – Here’s What Happened

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484 shares changed hands …

XERS +0.2% todayRead at source ↗
● ReutersSep 29, 2026 · 13:44 ET
Lundbeck expresses interest in buying Xeris, Bloomberg News reports

Danish drugmaker H Lundbeck A/S has expressed interest ​in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported ‌on Tuesday, citing people familiar with the matter.…

XERS +0.2% todayRead at source ↗
● Defense WorldSep 21, 2026 · 02:15 ET
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Recommendation of “Hold” by Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities rese…

XERS +0.2% todayRead at source ↗
● Seeking AlphaSep 9, 2026 · 15:17 ET
Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript…

XERS +0.2% todayRead at source ↗
● Business WireSep 9, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …

XERS +0.2% todayRead at source ↗
● Business WireAug 26, 2026 · 07:30 ETCOMPANY'S OWN WORDS
Xeris Announces Details for XP-8121 Program Overview Webinar

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range …

XERS +0.2% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just XERS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.